Molnupiravir

A planned interim analysis of 775 patients in Merck’s study found that 7.3% of those given molnupiravir were either hospitalized or had died by 29 days after treatment, compared with 14.1% of placebo patients. There were no deaths in the molnupiravir group, but there were eight deaths of placebo patients.

Merck to Seek FDA OK for Its COVID Pill After Trial Stopped Earlyhttps://www.medscape.com/viewarticle/960089?src=rss#vp_2

5 thoughts on “Molnupiravir

  1. I guess this is good news? Were any of the people treated vaccinated? Will people unwilling to receive a vaccination be willing to take a new medication? Maybe so, since at least in Florida they’re flocking to the monoclonal antibodies provided by governor Death-santis.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s